Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.

about

Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.

Item

http://www.wikidata.org/entity/Q55210410

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Will the reformed Cancer Drugs ...... f NICE cancer drug appraisals.

@en

Will the reformed Cancer Drugs ...... f NICE cancer drug appraisals.

@nl

type

Item

label

Will the reformed Cancer Drugs ...... f NICE cancer drug appraisals.

@en

Will the reformed Cancer Drugs ...... f NICE cancer drug appraisals.

@nl

prefLabel

Will the reformed Cancer Drugs ...... f NICE cancer drug appraisals.

@en

Will the reformed Cancer Drugs ...... f NICE cancer drug appraisals.

@nl

P1476

Will the reformed Cancer Drugs ...... f NICE cancer drug appraisals.

@en

P2093

Anna Schuh

http://www.w3.org/2001/XMLSchema#string

Mark R Middleton

http://www.w3.org/2001/XMLSchema#string

Richard W Barker

http://www.w3.org/2001/XMLSchema#string

Sarah Wordsworth

http://www.w3.org/2001/XMLSchema#string

Sian Rees

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?

Generalisability in economic evaluation studies in healthcare: a review and case studies.

Characterizing structural uncertainty in decision analytic models: a review and application of methods.

Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.

Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.

The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Criti

The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Pricing and reimbursement experiences and insights in the European Union and the United States: Lessons learned to approach adaptive payer pathways.

P2888

s12913-018-3162-2

P304

393

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12913-018-3162-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Liz Morrell

P577

2018-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104328118

http://www.w3.org/2001/XMLSchema#string

P698

29855313

http://www.w3.org/2001/XMLSchema#string

P921

reform

P932

5984433

http://www.w3.org/2001/XMLSchema#string